SOURCE: Cytovance Biologics, Inc.
OKLAHOMA CITY, OK--(Marketwired - Nov 5, 2013) - Cytovance Biologics, a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces Jesse McCool as Vice President of Microbial Services.
"Jesse's experience and exposure within the CMO industry is a tremendous asset to Cytovance," said Darren Head, President and Chief Executive Officer of Cytovance Biologics. "His depth of knowledge and experience in microbial fermentation especially in technological advancements are a great addition as we continue to enhance our microbial services pipeline."
Dr. McCool's experience in microbial services is an advantage for Cytovance as it expands its overall manufacturing capabilities, especially in the area of microbial fermentation. The expansion is a result of an increase in existing and new client contracts.
"The Cytovance Biologics' microbial team has made significant progress over the last two years in building out its microbial process development and cGMP capabilities," stated Dr. McCool. "The team is well positioned to realize enhancements across the microbial value stream from strain engineering to drug substance release and to become a leader in this space. I'm looking forward to helping our team to grow and our customers to find the right microbial solutions."
Prior to Cytovance, Dr. McCool was the Director of Process Development at Lonza. In this role he expanded offerings in Microbial R&D Services and improved market presence through driving new technologies development, particularly in the areas of Strain Development, Design-of-Experiments (DoE), and Process Characterization. He helped to adopt a QbD framework for supporting pre-validation activities and supported numerous cGMP campaigns as a subject matter expert. He also has significant experience in Six-Sigma and Operational Excellence.
Previous to Lonza, Dr. McCool served as Scientist at Mascoma Corporation in Lebanon, NH and Postdoctoral Research Associate at the Thayer School of Engineering at Dartmouth College, in Hanover, NH.
Dr. McCool holds a Ph.D. in Microbiology from the University of Massachusetts at Amherst. He recently completed advanced coursework in Microbial Physiology and Fermentation Technology at Technische Universiteit Delft in The Netherlands.
About Cytovance® Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com.